ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8. www.shennonbio.com
Location: United States, California, San Francisco
Employees: 11-50
Total raised: $13M
Founded date: 2021
Investors 3
| Date | Name | Website |
| - | DCVC | dcvc.com/ |
| 10.07.2026 | Future Ven... | future.ven... |
| 05.11.2022 | AV8 Ventur... | av8.vc |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.03.2023 | Seed | $13M | - |
Mentions in press and media 4
| Date | Title | Description |
| 15.03.2023 | San Francisco-based single cell platform Shennon Biotechnologies raises USD 13 million in funding | SAN FRANCISCO -Shennon Biotechnologies (“ShennonBio”), a biotech company developing more effective immunotherapies using a unique single-cell platform, announced a USD 13 million oversubscribed seed financing round, led by DCVC with partici... |
| 13.03.2023 | Shennon Biotechnologies Inks $13M Seed Round | SAN FRANCISCO, CA, Shennon Biotechnologies the close of a $13M oversubscribed seed financing round led by DCVC. >> Click here for more funding data on Shennon Biotechnologies >> To export Shennon Biotechnologies funding data... |
| 13.03.2023 | Shennon Biotechnologies Raises $13M in Seed Financing | Shennon Biotechnologies, a San Francisco, CA-based biotech company using a proprietary single cell platform to advance immunotherapies, raised $13M in Seed funding. The round was led by DCVC, with participation from Foundation Capital, AV8 ... |
| - | Shennon Biotechnologies | “Shennon Bio” |